Time Between Lucentis and Eylea Treatments Found To Be Similar

The principal difference between the two leading FDA-approved anti-VEGF drugs, Eylea and Lucentis for treatment of retinal hemorrhage has been accepted as the difference in length of time between injections. A new study, however, found no significant difference in injection scheduling between the drugs. The overall mean days between injections differed by only 1.8 days [Read More]

New Drug Effective in Treating Vitreous Traction

Early treatment with a new drug called JETREA® (formerly called ocriplasmin) has shown effectiveness in lessening the risk of macular pucker, macular hole, and vitreomacular traction (VMT). These conditions are caused by the tugging on the macula by the vitreous gel, which is attached to the retina at several points. As the vitreous shrinks with [Read More]

Non-Mydriatic Retinal Cameras Offer Safer Examination

by Liz Trauernicht, Director MD Foundation A significant amount of evidence finds that very bright light, especially blue light, can damage the macula. Traditional slit lamp devices used during eye exams produce high light levels, which may be problematic for people with macular degeneration. Before these devices can be used effectively, the pupil of the [Read More]

"As-Needed" Injections Are an Option for Wet AMD

Two-year results from the recently-completed HARBOR trial showed that some patients with wet AMD fare as well from Lucentis (ranibizumab) injections on an as-needed basis compared to a monthly basis. The original Lucentis trial recommended monthly dosing until the eye stabilized. The follow-up study, however, found that 93% of patients responded well with an average [Read More]

Medicare Approves Payment for Argus® II Retinal Prosthesis System

Payments Will Facilitate Beneficiary Access to Argus II in both Inpatient and Outpatient Settings  Sylmar, CA- August 15, 2013—Second Sight Medical Products, Inc. today announced that The Argus® II Retinal Prosthesis System (Argus II) has been approved by the Centers for Medicare and Medicaid Services (CMS) beginning October 1, 2013.  These payments are designed to support [Read More]